CRVS
Price
$6.16
Change
+$0.43 (+7.50%)
Updated
Sep 5 closing price
Capitalization
459.01M
53 days until earnings call
GLMD
Price
$1.36
Change
+$0.08 (+6.25%)
Updated
Sep 5 closing price
Capitalization
7.45M
64 days until earnings call
Interact to see
Advertisement

CRVS vs GLMD

Header iconCRVS vs GLMD Comparison
Open Charts CRVS vs GLMDBanner chart's image
Corvus Pharmaceuticals
Price$6.16
Change+$0.43 (+7.50%)
Volume$1.12M
Capitalization459.01M
Galmed Pharmaceuticals
Price$1.36
Change+$0.08 (+6.25%)
Volume$62.08K
Capitalization7.45M
CRVS vs GLMD Comparison Chart in %
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. GLMD commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a StrongBuy and GLMD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (CRVS: $6.16 vs. GLMD: $1.36)
Brand notoriety: CRVS and GLMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 223% vs. GLMD: 22%
Market capitalization -- CRVS: $459.01M vs. GLMD: $7.45M
CRVS [@Biotechnology] is valued at $459.01M. GLMD’s [@Biotechnology] market capitalization is $7.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileGLMD’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • GLMD’s FA Score: 1 green, 4 red.
According to our system of comparison, CRVS is a better buy in the long-term than GLMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 5 TA indicator(s) are bullish while GLMD’s TA Score has 5 bullish TA indicator(s).

  • CRVS’s TA Score: 5 bullish, 4 bearish.
  • GLMD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CRVS and GLMD are a good buy in the short-term.

Price Growth

CRVS (@Biotechnology) experienced а +7.32% price change this week, while GLMD (@Biotechnology) price change was +7.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

CRVS is expected to report earnings on Oct 30, 2025.

GLMD is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($459M) has a higher market cap than GLMD($7.45M). CRVS YTD gains are higher at: 15.140 vs. GLMD (-57.367). GLMD has higher annual earnings (EBITDA): -6.07M vs. CRVS (-35.45M). CRVS has more cash in the bank: 74.4M vs. GLMD (15.7M). GLMD has less debt than CRVS: GLMD (41K) vs CRVS (1.08M). CRVS (0) and GLMD (0) have equivalent revenues.
CRVSGLMDCRVS / GLMD
Capitalization459M7.45M6,159%
EBITDA-35.45M-6.07M584%
Gain YTD15.140-57.367-26%
P/E RatioN/A0.02-
Revenue00-
Total Cash74.4M15.7M474%
Total Debt1.08M41K2,641%
FUNDAMENTALS RATINGS
CRVS vs GLMD: Fundamental Ratings
CRVS
GLMD
OUTLOOK RATING
1..100
7452
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
80100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3786
P/E GROWTH RATING
1..100
9896
SEASONALITY SCORE
1..100
1285

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLMD's Valuation (33) in the Pharmaceuticals Other industry is in the same range as CRVS (61) in the Pharmaceuticals Major industry. This means that GLMD’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (80) in the Pharmaceuticals Major industry is in the same range as GLMD (100) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew similarly to GLMD’s over the last 12 months.

GLMD's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as CRVS (98) in the Pharmaceuticals Major industry. This means that GLMD’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Price Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for GLMD (86) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew somewhat faster than GLMD’s over the last 12 months.

GLMD's P/E Growth Rating (96) in the Pharmaceuticals Other industry is in the same range as CRVS (98) in the Pharmaceuticals Major industry. This means that GLMD’s stock grew similarly to CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSGLMD
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 16 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIVS2.510.25
+11.06%
VivoSim Lab Inc
DOCU79.863.62
+4.75%
DocuSign
CEVA22.730.36
+1.61%
CEVA
ASH54.910.67
+1.24%
Ashland
CNTB1.75-0.03
-1.69%
Connect Biopharma Holdings Limited

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+7.50%
SYRE - CRVS
43%
Loosely correlated
+0.06%
IPSC - CRVS
40%
Loosely correlated
+5.41%
TERN - CRVS
39%
Loosely correlated
+2.27%
RZLT - CRVS
35%
Loosely correlated
+8.40%
AMLX - CRVS
34%
Loosely correlated
+2.51%
More